Impact of a specialized oral nutritional supplement on quality of life in older adults following hospitalization: Post-hoc analysis of the NOURISH trial.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

Who Took Part

By PubMed's age tags, the people studied were older adults, both men and women.

The researchers analyzed data from the NOURISH trial-a randomized, placebo-controlled, multi-center, double-blind study conducted in patients with congestive heart failure, acute myocardial infarction, pneumonia, or chronic obstructive pulmonary disease.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

SF-36 and EQ-5D QoL outcomes were assessed at 0-, 30-, 60-, and 90-days post-discharge.

What Was Measured

Topics PubMed links to this paper include Quality of Life, Aftercare, Patient Discharge, Dietary Supplements, Hospitalization, Malnutrition and Nutritional Status.

Author keywords: Community, EuroQol 5-dimension scale, Older adults, Oral nutritional supplement (ONS) and Short-form (SF-36) health survey.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.